031 Living Young with Myeloma: Treatment, Relapse and a Breakthrough with CAR-T

Meera shares her powerful 15-year journey with multiple myeloma — from diagnosis during pregnancy to stem cell transplant, maintenance therapy and ultimately CAR-T treatment leading to remission.

📌Key Takeaways:

• CAR-T can work fast! Mira’s light chains became undetectable within weeks.
• Relapse doesn’t mean the end of options: new treatments are changing what’s possible.
• You are not alone: sharing real patient stories helps break the isolation of myeloma.

For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/

We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/

The Myeloma UK InfoLine is: 0800 980 3332

This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns

ABOUT YOUR HOSTS

Dr. Jam Kothari

Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.

Dr. Sally Moore

Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients. She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.